RT Journal Article
SR Electronic
T1 Wastewater monitoring using a novel, cost-effective PCR-based method that rapidly captures the transition patterns of SARS-CoV-2 variant prevalence (from Delta to Omicron) in the absence of conventional surveillance evidence
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.28.21268186
DO 10.1101/2022.01.28.21268186
A1 Chassalevris, Taxiarchis
A1 Chaintoutis, Serafeim C.
A1 Koureas, Michalis
A1 Petala, Maria
A1 Moutou, Evangelia
A1 Beta, Christina
A1 Kyritsi, Maria
A1 Hadjichristodoulou, Christos
A1 Kostoglou, Margaritis
A1 Karapantsios, Thodoris
A1 Papadopoulos, Agis
A1 Papaioannou, Nikolaos
A1 Dovas, Chrysostomos I.
YR 2022
UL http://medrxiv.org/content/early/2022/01/30/2022.01.28.21268186.abstract
AB Background The magnitude of Omicron SARS-CoV-2 variant of concern (VOC) global spread necessitates reinforcement of surveillance implementation. Conventional VOC surveillance based on genotyping of clinical samples is characterized by certain challenges related to available sequencing capacity, population sampling methodologies, and demands in terms of time, labor, and resources. Wastewater-based SARS-CoV-2 VOC surveillance constitutes a valuable supplementary practice, since it does not require extensive sampling, and provides information on the prevalence of the disease in a timely and cost-effective manner.Methods A highly sensitive real-time RT-PCR assay was developed, for targeted Omicron VOC detection and quantification in wastewater samples. The assay exclusively amplifies sequences with the S:Δ69/70 deletion, thus its performance is not hampered by the presence of the Delta VOC. The method was incorporated in the analysis of composite daily samples taken from the main Wastewater Treatment Plant (WWTP) of Thessaloniki, Greece from 1 December 2021 to 9 January 2022.Results The Omicron VOC was detected for the first time in samples from the Thessaloniki WWTP on 19 December 2021. In the following 10-day period, a rapid increase in Omicron sewage viral load was observed with an estimated early doubling time of 1.86 days. The proportion of the total SARS-CoV-2 load attributed to Omicron reached 91.09% on 7 January, revealing a fast Delta-to-Omicron VOC transition pattern. The detection of Omicron in wastewater preceded the outburst of reported (presumable) Omicron cases in the city by approximately 7 days.Conclusions The proposed wastewater-based surveillance approach enables rapid, real-time data acquisition on the Omicron VOC prevalence and transmission dynamics. Timely provision of these results to State authorities can readily influence the decision-making process for targeted public health interventions, including control measures, awareness, and preparedness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The entire study has been approved by the AUTH Research Ethics Committee, with reference number 25263/2022. The members of the AUTH Research Ethics Committee are: A/Prof. Dimitrios Stamovlasis (chair, School of Philosophy and Education, stadi@edlit.auth.gr), Prof. Ioannis Stefanidis (vice-chair, School of Law, AUTH, ids@law.auth.gr), Prof. Victoria Samanidou (School of Chemistry, AUTH, samanidu@chem.auth.gr), A/Prof Andreana Assimopoulou (Dept. of Chemical Engineering, AUTH, andreana@auth.gr), A/Prof Anastasia Tsingotjidou (School of Veterinary Medicine, AUTH, astsing@vet.auth.gr).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript